Όλο το DSpace

Πλοήγηση ανά Θέμα "plasmacytoma"

Αποτελέσματα 1-3 από 3

    • Immunohistochemicall expression of the p53, p21/Waf-1, Rb, p16 and Ki67 proteins in multiple myeloma 

      Kanavaros, P.; Stefanaki, K.; Vlachonikolis, J.; Papalazarou, D.; Rontogianni, D.; Arvanitis, D.; Antonakopoulos, G.; Gorgoulis, V.; Bai, M.; Agnantis, N. J. (2000)
      The aim of this study was to investigate the immunohistochemical expression of the proteins p53, Waf-l/p21, Rb, p16 and Ki67 in 38 cases of multiple myelomas (MM) and 4 cases of solitary extramedullary plasmacytomas in ...

    • Primary lymphomas of bone 

      Kitsoulis, P.; Vlychou, M.; Papoudou-Bai, A.; Karatzias, G.; Charchanti, A.; Agnantis, N. J.; Bai, M. (2006)
      Primary lymphomas of bone are uncommon malignancies. The vast majority of them are non-Hodgkin lymphoma (NHL), whereas primary Hodgkin lymphoma (HL) of bone is extremely rare. Patients with primary NHL of bone commonly ...

    • Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group 

      Katodritou E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., Kyrtsonis M.-C., Symeonidis A., Giannakoulas N., Vadikolia C., Michael M., Kalpadakis C., Gougopoulou T., Prokopiou C., Kaiafa G., Christoulas D., Gavriatopoulou M., Giannopoulou E., Labropoulou V., Verrou E., Kastritis E., Konstantinidou P., Anagnostopoulos A., Dimopoulos M.A. (2018)
      We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based ...